Categories AlphaGraphs, Earnings, Technology

SNAP Earnings: Snap slips to loss in Q2 despite strong sales growth

Multimedia messaging platform Snap, Inc. (NYSE: SNAP) reported a net loss for the second quarter of 2022, compared to a profit last year, despite sales growing in double digits. The results missed the consensus estimates.

Second-quarter net loss, on an adjusted basis, was $0.02 per share, compared to earnings of $0.10 in the same period of 2021. Analysts had predicted a narrower loss for the most recent quarter.

On an unadjusted basis, the company reported a net loss of $422.07 million or $0.26 per share in the June quarter, compared to a loss of $151.66 million or $0.10 per share in the second quarter of last year. Meanwhile, revenues increased 13% annually to $1.11 billion, which missed analysts’ forecast.


Check this space to read management/analysts’ comments on Snap’s Q2 2022 earnings


“We are evolving our business and strategy to reaccelerate revenue growth, including innovating on our products, investing heavily in our direct response advertising business, and cultivating new sources of revenue to help diversify our topline growth,” said Evan Spiegel, CEO of Snap.

Prior Performance

  • Snap Q1 2022 earnings infographic

_________________________________________________________________________________________________________________

Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock

_________________________________________________________________________________________________________________

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top